TMCnet - World's Largest Communications and Technology Community



Research and Markets: Nasopharyngeal Cancer - Pipeline Review, H1 2014: 6 Companies and 17 Drugs Profiled
[May 08, 2014]

Research and Markets: Nasopharyngeal Cancer - Pipeline Review, H1 2014: 6 Companies and 17 Drugs Profiled

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Nasopharyngeal Cancer - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary daabases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved:

  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Astex Pharmaceuticals, Inc.
  • Cyclacel Pharmaceuticals Inc.
  • National Cancer Centre Singapore

Drug Profiles:

  • nimotuzumab
  • MK-2206
  • CYC-202
  • Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes + [carboplatin]+ [gemcitabine]
  • Modified Vaccinia Ankara Vaccine
  • Cytokine-Induced Killer Cells + [cisplatin] + [gemcitabine]
  • Icotinib + [cisplatin] + [paclitaxel] + Radiation Therapy
  • EBV-Specific T-Lymphocytes
  • LMP Specific Cytotoxic T-Lymphocytes
  • HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes
  • EBV-Specific CTL Therapy
  • Therapeutic p53 Gene Agent
  • EBV-nRNA
  • AT-13387
  • Imidazoles
  • LMP2-TCR Gene Therapy
  • RO-5203280

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy